These recent advances of targeted therapy for BRAF p.V600E mutated CRC and immune checkpoint therapy for dMMR CRC highlight the importance of molecular testing, especially in late-onset CRC which harbors the highest incidence of BRAF p.V600E mutation and MMR deficiency. The gene discussed is BRAF; the disease is mismatch repair cancer syndrome 1.